Weight loss that matches bariatric surgery, delivered weekly by injection
Retatrutida is a triple agonist targeting GLP-1, GIP, and glucagon hormones, representing the next generation beyond Mounjaro's dual-agonist approach. Phase 3 TRIUMPH-4 trial involved 445 patients with obesity and knee osteoarthritis, showing 75.8% pain reduction alongside weight loss benefits.
- 28.7% average weight loss over 68 weeks in TRIUMPH-4 trial
- 445 patients with obesity and knee osteoarthritis tested
- 75.8% reduction in knee pain on standard pain scale
- Triple agonist targeting GLP-1, GIP, and glucagon hormones
- Seven additional phase 3 studies expected in 2026
Eli Lilly's experimental obesity drug retatrutida achieved 28.7% average weight loss over 68 weeks in phase 3 trials, matching bariatric surgery results and surpassing existing GLP-1 medications.
Eli Lilly announced the first results from its phase 3 clinical trials of retatrutida, an experimental obesity drug, and the numbers are striking. Over 68 weeks—roughly a year and a half—patients in the TRIUMPH-4 study lost an average of 28.7% of their body weight. For nearly a quarter of those taking the highest dose, the loss exceeded 35%. That places retatrutida in territory previously occupied only by bariatric surgery, which typically produces weight reductions between 25% and 35% in the first years after the procedure.
Retatrutida belongs to a family of medications called GLP-1 analogues, drugs that have already transformed how doctors treat type 2 diabetes and obesity. The most familiar name is semaglutida—the active ingredient in Ozempic and Wegovy, made by the Danish company Novo Nordisk. These drugs work by mimicking a hormone the body produces naturally. In the pancreas, they trigger insulin production. In the stomach, they slow digestion. In the brain, they activate the sensation of fullness. The result is straightforward: people feel less hungry, eat fewer calories, and lose weight.
But retatrutida represents a step forward even within this already-revolutionary class. Eli Lilly's earlier drug, Mounjaro, was itself a leap ahead because it acts on two hormonal pathways instead of one—it mimics both GLP-1 and another intestinal hormone called GIP. That dual action proved more effective than semaglutida alone. Semaglutida produces roughly 17.4% weight loss after 68 weeks. Mounjaro achieves about 20.9% over 72 weeks, climbing to 25.3% at 88 weeks. Retatrutida goes further still by targeting three pathways: it mimics GLP-1, GIP, and glucagon, a third hormone involved in metabolism. The result is the most dramatic weight loss yet observed in this drug category.
The TRIUMPH-4 trial tested retatrutida in 445 adults with obesity or overweight and knee osteoarthritis. One-third received a weekly injection of 9 milligrams, one-third received 12 milligrams, and one-third received placebo. Patients started at 2 milligrams and increased by 2 milligrams every four weeks until reaching their target dose. Beyond weight loss, the study measured something else: pain. Patients with knee osteoarthritis who took retatrutida experienced a 75.8% reduction in pain on a standard scale. That secondary finding matters because obesity and joint damage often occur together, and excess weight worsens both conditions. Kenneth Custer, a Lilly executive, noted that patients with this combination frequently face limited mobility and may eventually need joint replacement surgery. The drug appeared to address both problems simultaneously.
The side effects were consistent with other drugs in the class. Nausea affected 43.2% of those on the highest dose. Diarrhea occurred in 33.1%, constipation in 25%, and vomiting in 20.9%. A smaller group—20.9%—experienced disestesia, unusual sensations related to touch, though Lilly reported these were generally mild and rarely caused patients to stop treatment. The drug was deemed safe overall, with adverse events classified as mild to moderate.
Retatrutida is not yet available. The TRIUMPH-4 results represent the first public disclosure from phase 3 testing, the final stage before regulatory review. Lilly expects results from seven additional phase 3 studies in 2026. The company anticipates seeking approval for patients with significant weight loss needs and certain complications, including knee osteoarthritis. None of these weight-loss drugs are currently covered by Brazil's public health system; all are available only through private pharmacies at substantial cost. If retatrutida reaches the market, it will join a crowded field of injectable treatments, each with slightly different efficacy profiles and price points. What distinguishes retatrutida is not just the magnitude of weight loss but the speed at which it achieves it—28.7% in 68 weeks represents a new benchmark for pharmaceutical intervention in obesity.
Citas Notables
People with obesity and knee osteoarthritis often live with pain and limited mobility and may eventually need joint replacement. We are encouraged by TRIUMPH-4 results, which highlight retatrutida's powerful effect on body weight, pain, and physical function.— Kenneth Custer, Eli Lilly executive vice president
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this drug works as well as surgery? Isn't surgery already proven?
Surgery is permanent and irreversible, but it carries real risks—infection, complications, sometimes regret. A weekly injection you can stop anytime is a different kind of tool. For people who want to avoid surgery or can't access it, this changes the calculation entirely.
The pain reduction seems almost secondary in the reporting, but 75.8% is enormous. Why isn't that the headline?
Because weight loss is what people came for. But you're right—the pain reduction might be the more durable benefit. Weight can come back if someone stops the drug. Joint pain that improves because you're lighter and moving better might stick around longer.
What about the nausea? Forty-three percent is a lot of people feeling sick.
It is. But the source says it was mild to moderate and rarely made people quit. That's different from intolerable. Still, it's a real trade-off. You lose weight but you feel queasy for months. Not everyone will accept that bargain.
Seven more studies coming in 2026. Does that suggest Lilly isn't confident, or just being thorough?
Thorough. Phase 3 is the final gate before regulators decide. Multiple studies in different populations strengthen the case. It's also smart business—more data means more ways to market the drug to different patient groups.
These drugs aren't on the public health system. Does that limit who actually benefits?
Dramatically. In Brazil, like most countries, these are expensive private medicines. So the headline is true—retatrutida works as well as surgery—but only for people who can afford it. That's the gap between what the science can do and what the system allows.